[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extracorporeal-life-support\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extracorporeal-life-support":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100450503",false,"NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.","ALL",{"count":18,"type":19},3000,"ESTIMATED","3 Months","OBSERVATIONAL","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Septic Shock","Acute Respiratory Distress Syndrome","Trauma","Rhabdomyolysis","Cardiogenic Shock","Pancreatitis","Acute on Chronic Liver Failure","Acute Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Hemophagocytic Lymphohistiocytoses","Liver Transplant; Complications","Infectious Disease","Postoperative Vasoplegic Syndrome","Drug Overdose","Sepsis","RECRUITING","2025-09-10",{"date":45,"type":46},"2025-09-11","ACTUAL",{"date":48,"type":46},"2022-06-22",{"date":50,"type":19},"2032-09",{"name":52,"class":53},"CytoSorbents, Inc","INDUSTRY",28,{"id":56,"slug":4,"hasResults":10,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":10,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":66,"studyType":21,"phases":4,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100387892","NCT04330651","Post-Surgery Extracorporeal Life Support","Outcomes' Predictors in Post-Surgery Extracorporeal Life Support","PC-ECLS","Inclusion Criteria:\n\n* Patients underwent cardiac surgery\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","18 Years","80 Years",{"count":65,"type":19},500,"20 Years","Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild\u002Fterm outcome will be investigated.",[28,34,69,70,71],"Extracorporeal Membrane Oxygenation Complication","Post Cardiac Arrest Syndrome","Post-cardiac Surgery",[73,74,75,76,77,78],"extracorporeal life support","ecls","ecmo","outocome","prognostic factors","extracorporeal membrane oxygenation","2021-04-27",{"date":81,"type":46},"2021-04-28",{"date":83,"type":4},"2004-01",{"date":85,"type":19},"2029-01-31",{"name":87,"class":88},"University of Florence","OTHER",1,""]